TELIX Pharmaceuticals Ltd (TLX) — Cash Flow-to-Debt Ratio
TELIX Pharmaceuticals Ltd (TLX) has a Cash Flow-to-Debt Ratio of 0.04x as of June 2025, meaning its operating cash flow of AU$27.98 Million could theoretically repay 0% of its total liabilities (AU$768.01 Million) in one year. See TLX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
TELIX Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for TELIX Pharmaceuticals Ltd across 8 annual periods. Also explore TELIX Pharmaceuticals Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for TELIX Pharmaceuticals Ltd (2017–2024)
Year-by-year debt coverage analysis for TELIX Pharmaceuticals Ltd. For market capitalisation and broader financial context, see TELIX Pharmaceuticals Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.05x | AU$43.03 Million | AU$948.22 Million | ▼ -52.6% |
| 2023 | 0.10x | AU$23.88 Million | AU$249.39 Million | ▲ +126.7% |
| 2022 | -0.36x | AU$-63.97 Million | AU$178.44 Million | ▲ +35.8% |
| 2021 | -0.56x | AU$-59.33 Million | AU$106.17 Million | ▼ -2346.7% |
| 2020 | 0.02x | AU$1.96 Million | AU$78.81 Million | ▲ +103.4% |
| 2019 | -0.73x | AU$-23.33 Million | AU$31.88 Million | ▲ +16.0% |
| 2018 | -0.87x | AU$-20.75 Million | AU$23.80 Million | ▲ +74.0% |
| 2017 | -3.35x | AU$-6.03 Million | AU$1.80 Million | — |